Terns Pharmaceuticals Inc
430
Company Profile
Business description
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
Contact
1065 East Hillsdale Boulevard
Suite 100
FosterCA94404
USAT: +1 650 525-5535
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
stocks
US dividend shares are getting a boost from the HALO trade. Can it last?
Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.
stocks
Unconventional wisdom: A modern day bank run
Is the economy and investor portfolios at risk from a potential ‘bank run’ in private credit?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,863.20 | 50.40 | 0.57% |
| CAC 40 | 7,984.44 | 72.92 | -0.91% |
| DAX 40 | 23,589.65 | 50.38 | -0.21% |
| Dow JONES (US) | 46,677.85 | 739.42 | -1.56% |
| FTSE 100 | 10,305.15 | 48.62 | -0.47% |
| HKSE | 25,597.44 | 119.32 | -0.46% |
| NASDAQ | 22,311.98 | 404.16 | -1.78% |
| Nikkei 225 | 53,786.40 | 666.56 | -1.22% |
| NZX 50 Index | 13,159.21 | 40.08 | -0.30% |
| S&P 500 | 6,672.62 | 103.18 | -1.52% |
| S&P/ASX 200 | 8,642.50 | 54.60 | 0.64% |
| SSE Composite Index | 4,118.58 | 10.52 | -0.25% |